Patent Grant
10857093
The disclosure relates generally to methods for making or fabricating the delivery systems for administering a therapeutic agent or drug using an array of microstructures, methods for using the systems for delivery of an agent, and related features thereof.
Arrays of microneedles were proposed as a way of administering drugs through the skin in the 1970s, for example in expired U.S. Pat. No. 3,964,482. Microneedle or microstructure arrays can facilitate the passage of drugs through or into human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microstructure arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
In recent years it has become more feasible to manufacture microstructure arrays in a way that makes their widespread use financially feasible. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing microneedle arrays. If the arrays are sufficiently inexpensive, for example, they may be marketed as disposable devices. A disposable device may be preferable to a reusable one in order to avoid the question of the integrity of the device being compromised by previous use and to avoid the potential need of resterilizing the device after each use and maintaining it in controlled storage.
Despite much initial work on fabricating microneedle arrays in silicon or metals, there are significant advantages to polymeric arrays. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing polymeric microneedle arrays. Arrays made primarily of biodegradable polymers also have some advantages. U.S. Pat. No. 6,945,952 and U.S. Published Patent Applications Nos. 2002/0082543 and 2005/0197308 have some discussion of microneedle arrays made of biodegradable polymers. A further description of the fabrication of a microneedle array made of polyglycolic acid is found in Park et al, “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery,” J. of Controlled Release, 104:51-66 (2005).
A method of forming microprotrusion arrays using solvent casting methods is described in U.S. Publication Nos. 2008/0269685 and 2014/0272101, which are incorporated in their entirety herein by reference.
A layered microstructure array has been described in U.S. Publication No. 2011/0276028, incorporated in its entirety herein, for hPTH delivery comprising a fast dissolving drug-in-tip distal layer and a backing layer formed of an insoluble biodegradable polymer.
Despite these efforts, there is still a need to find simpler and better methods for the manufacture of polymeric delivery systems. A particular need is for systems and methods that provide better, more consistent and easier formation of the arrays as well as providing methods that are useful for commercial manufacture of arrays. A further need is for a method of forming microstructure arrays that is scalable from small scale, aseptic and pilot testing to commercial processes.
The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.
The following aspects and embodiments thereof described and illustrated below are meant to be exemplary and illustrative, not limiting in scope.
In one aspect, a method of making or preparing an array of microstructures. In some embodiments, the method comprises dissolving or suspending at least one therapeutic or active agent in a first solvent to form a therapeutic or active agent solution or suspension. At least one polymer is dissolved in a second solvent, which may be the same or different than the first solvent, to form a polymer matrix solution or suspension. In some embodiments, at least one of the first or second solvent is water or an aqueous solution. The therapeutic or active agent solution or suspension and the polymer solution are mixed to form a polymer matrix solution or suspension.
In some embodiments, the therapeutic or active agent solution or suspension and/or the polymer solution or suspension includes one or more excipients and/or additives. In some embodiments, the excipient or additive is selected from one or more of a sugar, a surfactant, or an antioxidant. In some embodiments, one or more of the excipients or additives is dissolved in at least one of the first or second solvent. In some embodiments, the sugar is selected from sorbitol, sucrose, trehalose, fructose, or dextrose. In some embodiments, the surfactant is selected from Polysorbate 20 or Polysorbate 80. In some embodiments, the antioxidant is selected from methionine, cysteine, D-alpha tocopherol acetate, EDTA, or vitamin E. Where the excipient is a sugar, in some embodiments the at least one sugar is dissolved in the polymer matrix or suspension after the polymer is dissolved in the solvent.
In embodiments, the therapeutic or active agent is selected from one or more of a drug, a small molecule, a peptide or a protein, and/or a vaccine.
A low vacuum is applied to a mold having a plurality of microstructure cavities formed therein. The polymer matrix solution or suspension is dispensed on the mold and the microstructure cavities in the mold are filled with the polymer matrix solution or suspension. The solution or suspension is dried to form the array of microstructures. In embodiments, the low vacuum is applied to achieve a vacuum pressure of about 1×10−3 to 760 Torr. In other embodiments, the low vacuum is applied to achieve a vacuum pressure of about 25 to 760 Torr. In some embodiments, the dispensing and/or filling steps are performed outside the low vacuum. In some embodiments, excess polymer matrix solution or suspension is removed from the mold, including the mold surface, after the filling step.
In some embodiments, the method further comprises dispensing at least one soluble gas into the cavities prior to applying the low vacuum to the mold. In some embodiments, the method further comprises dispensing at least one soluble gas into the cavities prior to dispensing the polymer matrix solution or suspension on the mold. In some embodiments, the soluble gas is selected from CO2 and CH4.
In some embodiments, the polymer matrix solution or suspension is dried at a temperature of about 5-50° C. In some embodiments, the polymer matrix solution or suspension is dried for at least about 30-60 minutes.
In some embodiments, the method further comprises dispensing a basement or backing layer formulation on the mold surface. In embodiments, the basement or backing layer formulation is dispensed such that the basement or backing layer formulation contacts the polymer matrix to connect the dried microstructure (polymer matrix) portions. In some embodiments, the basement or backing layer formulation is dried in an oven at about 5-50° C. In some embodiments, the basement or backing layer is comprised of at least one non-biodegradable polymer.
In some embodiments, the basement or backing layer is affixed to a substrate. In some embodiments, the substrate is selected from a pressure sensitive adhesive and a UV cured adhesive.
In some embodiments, the method further comprises demolding the array from the mold. In some embodiments, the array is demolded from the mold drying the basement or backing layer.
Additional embodiments of the present microstructures, arrays, methods, apparatuses, devices, and the like, will be apparent from the following description, drawings, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.
It will be appreciated that the thicknesses and shapes for the various microstructures have been exaggerated in the drawings to facilitate understanding of the device. The drawings are not necessarily “to scale.”
Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.
The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g.; A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Morrison and Boyd, Organic Chemistry (Allyn and Bacon, Inc., current addition); J. March, Advanced Organic Chemistry (McGraw Hill, current addition); Remington: The Science and Practice of Pharmacy, A. Gennaro, Ed., 20th Ed.; Goodman & Gilman The Pharmacological Basis of Therapeutics, J. Griffith Hardman, L. L. Limbird, A. Gilman, 10th Ed.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also explicitly disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
As used in this specification, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “polymer” includes a single polymer as well as two or more of the same or different polymers; reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions described below.
The terms “microprotrusion”, “microprojection”, “microstructure” and “microneedle” are used interchangeably herein to refer to elements adapted to penetrate or pierce at least a portion of the stratum corneum or other biological membrane. For example, illustrative microstructures may include, in addition to those provided herein, microblades as described in U.S. Pat. No. 6,219,574, edged microneedles as described in U.S. Pat. No. 6,652,478, and microprotrusions as described in U.S. Patent Publication No. U.S. 2008/0269685.
In discussing the applicators and arrays described herein, the term “downward” is sometimes used to describe the direction in which microprotrusions are pressed into skin, and “upward” used to describe the opposite direction. However, those of skill in the art will understand that the applicators can be used where the microprotrusions are pressed into skin at an angle to the direction of the earth's gravity, or even in a direction contrary to that of the earth's gravity. In many applicators, the energy for pressing the microprotrusions is provided primarily by an energy-storage member and so efficiency is not much affected by the orientation of the skin relative to the earth's gravity.
In this application reference is often made for convenience to “skin” as the biological membrane which the microprojections penetrate. It will be understood by persons of skill in the art that in most or all instances the same inventive principles apply to the use of microprojections to penetrate other biological membranes such as, for example, those which line the interior of the mouth or biological membranes which are exposed during surgery.
“Biodegradable” refers to natural or synthetic materials that degrade enzymatically, non-enzymatically or both to produce biocompatible and/or toxicologically safe by-products which may be eliminated by normal metabolic pathways.
“Medium vacuum” refers to a partial pressure that may be achieved with a vacuum pump. A medium pressure may not be measurable using a liquid or mechanical manometer. In embodiments, a medium vacuum refers to a pressure of about 25 to 1×10−3 Torr.
The term “microprotrusion array” for purposes herein is intended to denote a two-dimensional or a three-dimensional arrangement of microprotrusions, microstructures, microprojections, or microneedles, which are used interchangeably herein. The arrangement may be regular according to a repeating geometric pattern or it may be irregular. A typical “microstructure array”, “microprojection array”, or “microneedle array” comprises microstructures, microprojections, or microneedles projecting from a base or substrate of a particular thickness, which may be of any shape, for example square, rectangular, triangular, oval, circular, or irregular. An array typically comprises a plurality of microstructures, microprojections, or microneedles. The microstructures, microprojections, or microneedles themselves may have a variety of shapes. While an array could be pressed by hand into skin, a variety of devices may be used to hold the array as it is being applied and/or to facilitate in one way or another the process of application of the array to the skin or other biological membrane. Such devices may broadly be referred to as “applicators.” Applicators may for example reduce the variations in force, velocity, and skin tension that occur when an array is pressed by hand into the skin. Variations in force, velocity and skin tension can result in variations in permeability enhancement.
“Non-biodegradable” refers to natural or synthetic materials that do not appreciably degrade when inserted into and/or contacted with skin, mucosa, or other biological membrane for a period of time associated with use of microstructure arrays.
“Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
“Rough vacuum” or “low vacuum” refers to a partial pressure of less than 1 atmosphere (760 Torr). In embodiments, a rough or low vacuum refers to a pressure of about 760 to 25 Torr.
“Substantially” or “essentially” means nearly totally or completely, for instance, 90-95% or greater of some given quantity.
“Transdermal” refers to the delivery of an agent into and/or through the skin for local and/or systemic therapy. The same inventive principles apply to administration through other biological membranes such as those which line the interior of the mouth, gastro-intestinal tract, blood-brain barrier, or other body tissues or organs or biological membranes which are exposed or accessible during surgery or during procedures such as laparoscopy or endoscopy.
A material that is “water-soluble” may be defined as soluble or substantially soluble in aqueous solvents, such that the material dissolves into, within or below the skin or other membrane which is substantially aqueous in nature.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
Before describing the methods of manufacture in detail, it is to be understood that the methods are not limited to specific solvents, materials, or device structures, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
Examples of forming various microstructure arrays using different formulations and configurations are provided in Example 1.
A. Array Molds
The molds used to form the arrays in the methods herein can be made using a variety of methods and materials. Exemplary molds and methods of making molds are described, for example, in U.S. Patent Publication No. 2008/2696585. In one exemplary embodiment, the mold is a negative mold formed from a silicone such as polydimethylsilicone. A negative mold is typically formed by preparing a master microprojection array and casting a liquid mold material over the master array. The mold is allowed to dry and harden, which results in a mold comprising cavities corresponding to the microprojections of the master array. It will be appreciated that the molds suitable for use in the present methods may be prepared according to other methods.
In general, the microprojections have a height of at least about 100 μm, at least about 150 μm, at least about 200 μm, at least about 250 μm, or at least about 300 μm. In general it is also preferred that the microprojections have a height of no more than about 1 mm, no more than about 500 μm, no more than about 300 μm, or in some cases no more than about 200 μm or 150 μm. In embodiments, the microprojections have a height of at least about 50-500 μm. In other embodiments, the microprojections have a height of at least about 100-500 μm, 100-400 μm, 100-300 μm, 100-200 μm, 100-150 μm, 150-500 μm, 150-400 μm, 150-300 μm, 150-200 μm, 200-500 μm, 200-400 μm, 200-300 μm, 300-500 μm, 300-400 μm, or 400-500 μm. It will be appreciated that the microprojections within an array may have a range of heights. The microprojections may have any suitable shape including, but not limited to polygonal or cylindrical. Particular embodiments include pyramidal including a four-sided pyramid, a funnel shape, a cylinder, a combination of funnel and cylinder shape having a funnel tip and a cylindrical base, and a cone with a polygonal bottom, for example hexagonal or rhombus-shaped. Other possible microprojection shapes are shown, for example, in U.S. Published Patent Apps. 2004/0087992 and 2014/0180201. Microprojections may in some cases have a shape which becomes thicker towards the base, for example microprojections which have roughly the appearance of a funnel, or more generally where the diameter of the microprojection grows faster than linearly with distance to the microprojection distal end. It will be appreciate that polygonal microprojections may also have a shape which becomes thicker toward the base or where a radius or diameter grows faster than linearly with distance to the microprojection distal end. Where microprojections are thicker towards the base, a portion of the microprojection adjacent to the base, which may be called the “foundation,” may be designed not to penetrate the skin.
The microprojections may be spaced about 0-500 μm apart. In specific, but not limiting embodiments, the microprojections are spaced about 0 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, or about 500 μm apart. The space between the microprojections may be measured from the base of the microprojections (base to base) or from the tip (tip to tip). The spacing of the microprojections may be regular or irregular.
One exemplary master array includes a plurality of diamond shaped projections having a height of about 200 μm, a base of about 70 μm, and spacing between the projections of about 200 μm. In another exemplary embodiment, the master array includes a plurality of hexagonal or other polygonal shaped projections having a height of about 200 μm, a base of about 70 μm, and spacing between the projections of about 400 μm. In yet another embodiment, the master array includes a plurality of cylindrical shaped projections having a height of about 400 μm, a diameter of about 100 μm, and spacing between the projections of about 200 μm. It will be appreciated that the cylindrical shaped projections may have a funnel shaped, pointed, or sharp distal end.
B. Preparation of Casting Solution or Formulation
For the active agent containing portion of the microstructures, a casting solution or formulation is formed by dissolving or suspending one or more therapeutic agents, active agents, drugs, APIs, or other substances to be transdermally delivered and one or more polymers in a solvent to form a polymer matrix solution or suspension. The terms active agent, therapeutic agent, agent, drug, API are used interchangeably herein and discussion or reference to one is intended to include and apply to each and all terms. In one embodiment, the casting solution is formed by dissolving or suspending at least one agent and one or more polymers in an aqueous buffer or solvent to form a solution or suspension comprising the active agent and the polymer. In another embodiment, at least one active agent is dissolved or suspended in a solvent to form an active agent solution or suspension. At least one polymer is separately dissolved in a solvent to form a polymer solution or suspension. The suspension may be a liquid in liquid suspension or a solid in liquid suspension depending on the nature of the active agent and/or polymer. The solvent used for the active agent solution and the polymer solution may be the same or different. The active agent solution and the polymer solution are mixed to form a polymer matrix solution or suspension. It will further be appreciated that a solvent mixture may be used to dissolve or suspend the active agent and/or polymer.
Casting solvents are preferably aqueous solvents. Suitable aqueous solvents include, but are not limited to, water, alcohols (for example, C1 to C8 alcohols such as propanol and butanol), alcohol esters, or mixtures of thereof. In other embodiments, the solvents are non-aqueous. Suitable non-aqueous solvents include, but are not limited to, esters, ethers, ketones, nitrites, lactones, amides, hydrocarbons and their derivatives as well as mixtures thereof. In other non-limiting embodiments, the solvent is selected from acetonitrile (ACN), dimethyl sulfoxide (DMSO), water, or ethanol. It will be appreciated that the choice of solvent may be determined by one or more properties of the active agent and/or polymer. It will further be appreciated that the casting solvent may comprise a mixture of solvents.
Any suitable drug, therapeutic agent, API, or other active agent may be dissolved or suspended in the solvent. The present arrays are suitable for a wide variety of substances or agents. Suitable active agents that may be administered include the broad classes of compounds such as, by way of illustration and not limitation: analeptic agents; analgesic agents; antiarthritic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; anxiolytics; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular preparations including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents; caustic agents; central nervous system stimulants; cough and cold preparations, including decongestants; cytokines; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; keratolytic agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; pain relieving agents such as anesthetic agents; parasympatholytics; peptide drugs; proteolytic enzymes; psychostimulants; respiratory drugs, including antiasthmatic agents; sedatives; steroids, including progestogens, estrogens, corticosteroids, androgens and anabolic agents; smoking cessation agents; sympathomimetics; tissue-healing enhancing agents; tranquilizers; vasodilators including general coronary, peripheral and cerebral; vessicants; and combinations thereof.
In embodiments, the active agent is a biological agent including, but not limited to peptides, polypeptides, proteins, or nucleic acids (e.g. DNA or RNA). In one embodiment, the active agent is a polypeptide such as human parathyroid hormone (e.g. hPTH(1-34)), a protein such as human growth hormone, or an antibody. Examples of peptides and proteins which may be used with the microstructure arrays include, but are not limited to, parathyroid hormone (PTH), oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, nerve growth factor, blood coagulation factors VII and IX, lysozyme chloride, renin, bradykinin, tyrocidin, gramicidines, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet derived growth factor, growth hormone releasing factor, bone morphogenic protein, and synthetic analogues and modifications and pharmacologically active fragments thereof. Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof. Administration of oligonucleotides is also contemplated, and includes DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof. Therapeutic antibodies include Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
In other embodiments, at least a portion of the distal layer comprises an agent suitable for use as a prophylactic and/or therapeutic vaccine. In an embodiment, the vaccine comprises an antigen epitope conjugated on or to a carrier protein. It will be appreciated that vaccines may be formulated with our without an adjuvant. Suitable vaccines include, but are not limited to, vaccines for use against anthrax, diphtheria/tetanus/pertussis, hepatitis A, hepatitis B, Haemophilus influenzae type b, human papillomavirus, influenza, Japanese encephalitis, measles/mumps/rubella, meningococcal diseases (e.g., meningococcal polysaccharide vaccine and meningococcal conjugate vaccine), pneumococcal diseases (e.g., pneumococcal polysaccharide vaccine and meningococcal conjugate vaccine), polio, rabies, rotavirus, shingles, smallpox, tetanus/diphtheria, tetanus/diphtheria/pertussis, typhoid, varicella, and yellow fever.
Additional agents include those directed against avian (pandemic) influenza virus, Campylobacter sp., Chlamydia sp., Clostridium botulinum, Clostridium difficile, dengue fever virus, E. coli, Ebola virus, Epstein Barr virus, nontypeable Haemophilus influenzae, hepatitis C, hepatitis E, herpes viruses including herpes zoster, HIV, leishmanial and malarial parasites, meningococcal serogroup B, nicotine, parainfluenza, ragweed allergen, respiratory syncytial virus (RSV), Rift Valley fever virus, SARS-associated coronavirus, Shigella sp., Staphylococcus aureus, Streptococcus Group A (GAS), Streptococcus Group B (GBS), tick-borne encephalitis, Venezuelan equine encephalitis, and West Nile virus.
It will be appreciated agents include those typically used for veterinary uses including vaccines for cats, dogs and other small animals as well as those for use with livestock such as cattle, pigs, goats, horses, chickens, etc. Veterinary agents include those directed against parvovirus, distemper virus, adenovirus, parainfluenza virus, Bortadella bronchiseptica, Leptospira spp., Borrelia burgdorferi, feline herpesvirus, feline calcivirus, feline panleukopenia virus, feline leukemia virus, feline immunodeficiency virus, and Chlamydia felis. Veterinary agents further include those directed against viral respiratory diseases (infectious bovine rhinotracheitis—IBR, bovine viral diarrhea—BVD parainfluenza-3 virus—Pl3, bovine respiratory syncytial virus—BRSV), Campylobacter fetus (Vibriosis) Leptospirosis sp., Trichomoniasis, Moraxella bovis (pinkeye), Clostridial (Blackleg), Brucellosis, Mannheimia haemolytica, Pasteurella multocida, Haemophilus somni, Escherichia coli, Anaplasmosis, foot-and-mouth disease virus (FMDV), procine parvovirus, swine fever, porcine reproductive and respiratory syndrome virus (PRRS), swine influenza, transmissible gastro enteritis virus (TGE), Staphylococcus hyicus, Actinobacillus pleuropneumonia, Atrophic rhinitis, Enzootic pneumonia, Haemophilus parasuis, Streptococcal meningitis, Mycoplasma gaffisepticum, Salmonella, Marek's Disease virus, and infectious bronchitis virus. Further veterinary agents include those directed against Eastern/Western Equine Encephalomyelitis, Equine influenza, Potomac Horse Fever, Strangles, Equine Herpesvirus, and Equine Viral Arteritis.
It will be appreciated that the vaccines described herein may include one or more antigens and one or more adjuvants. For example, the seasonal flu vaccine typically includes agents directed against several strains of influenza. Where multiple antigens are included in the vaccine, the antigens may be directed to conferring an immune response to one or more bacteria, virus, or microorganism. For example, more than one antigen specific to the same bacteria, virus or microorganism may be included in the vaccine. Alternatively, multiple antigens specific to different bacteria, viruses, or microorganisms may be included in the vaccine. Where the vaccine includes multiple antigens, the vaccine may include multiple adjuvants. The number of adjuvants included in the vaccine may be the same, less or more than the number of corresponding antigens included in the vaccine. In an embodiment, a vaccine including a single antigen may include multiple adjuvants.
In another embodiment, at least a portion of the distal layer comprises an agent suitable for veterinary uses. Such uses include, but are not limited to, therapeutic and diagnostic veterinary uses.
Polymers for use in the methods are typically biocompatible. In one embodiment, at least some of the polymers are biodegradable.
In an embodiment, the polymer is a structure-forming polymer. In an embodiment, the polymer is a hydrophilic water soluble polymer. Suitable polymers are known in the art and described, for example, in U.S. Patent Application No. 2008/0269685. Exemplary biocompatible, biodegradable, or bioerodible polymers include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid)s (PLGAs), polyanhydrides, polyorthoesters, polyetheresters, polycaprolactones (PCL), polyesteram ides, poly(butyric acid), poly(valeric acid), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), polyethylene glycol (PEG), block copolymers of PEG-PLA, PEG-PLA-PEG, PLA-PEG-PLA, PEG-PLGA, PEG-PLGA-PEG, PLGA-PEG-PLGA, PEG-PCL, PEG-PCL-PEG, PCL-PEG-PCL, copolymers of ethylene glycol-propylene glycol-ethylene glycol (PEG-PPG-PEG, trade name of Pluronic® or Poloxamer®), block copolymers of polyethylene glycol-poly(lactic acid-co-glycolic acid) (PLGA-PEG), dextran, hetastarch, tetrastarch, pentastarch, hydroxyethyl starches, cellulose, hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (Na CMC), thermosensitive HPMC (hydroxypropyl methyl cellulose), polyphosphazene, hydroxyethyl cellulose (HEC), polysaccharides, polyalcohols, gelatin, alginate, chitosan, hyaluronic acid and its derivatives, collagen and its derivatives, polyurethanes, and copolymers and blends of these polymers. One hydroxyethyl starch may have a degree of substitution of in the range of 0-0.9. An exemplary polysaccharide is dextran including dextran 70, dextran 40, and dextran 10.
The casting solution may further include one or more excipients dissolved or suspended in the buffer or solvent. Suitable excipients include, but are not limited to, one or more stabilizers, plasticizers, surfactants, and/or anti-oxidants.
In one embodiment one or more sugars is added to the casting solution. Sugars can stabilize the active ingredient and/or plasticize at least one of the polymers. Sugars may also be used to affect, moderate, or regulate degradation of the polymer(s). Exemplary sugars include, but are not limited to, dextrose, fructose, galactose, maltose, maltulose, iso-maltulose, mannose, lactose, lactulose, sucrose, and trehalose, and sorbitol. In other embodiments, a sugar alcohol as known in the art is included in the casting solution. Exemplary sugar alcohols include, but are not limited to, lactitol, maltitol, sorbitol, and mannitol. Cyclodextrins can also be used advantageously in microprojection arrays, for example α, β, and γ cyclodextrins. Exemplary cyclodextrins include hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin. In other embodiments, where Dextran, hetastarch and/or tetrastarch is used as a polymer in the casting solution, sorbitol may preferably be included in the casting solution. In this embodiment, sorbitol may not only stabilize the active agent, but also plasticize the polymer matrix, which reduces brittleness. The biodegradability or dissolvability of the microprojection array may be facilitated by the inclusion of sugars. Sugars and sugar alcohols may also be helpful in stabilization of peptides, proteins, or other biological active agents and in modifying the mechanical properties of the microprojections by exhibiting a plasticizing-like effect. Where the active agent is a biological agent including, but not limited to, peptides, proteins, and antibodies, one or more sugars or sugar alcohols may be used in the casting solution as a stabilizing agent. The sugar may be added to (i) the therapeutic agent solution or suspension, (ii) the polymer solution or suspension, or (iii) the polymer matrix solution or suspension once (i) and (ii) have been mixed.
One or more surfactants may be added to the casting solution to change the solutions' surface tension and/or reduce the hydrophobic interactions of proteins. Any suitable surfactant as known in the art may be used. Exemplary surfactants include, but are not limited to, emulsifiers such as Polysorbate 20 and Polysorbate 80.
One or more antioxidants may be added to the casting solution. Any suitable antioxidant as known in the art may be used. Exemplary antioxidants include, but are not limited to, methionine, cysteine, D-alpha tocopherol acetate, EDTA, and vitamin E.
C. Formation of Microstructure Arrays
In a general method, a casting solution is dispensed onto the mold or into the mold cavities. The casting solution is moved into the cavities. The casting solution is dried to form a solid polymer. Optionally, a backing or basement layer is cast on the mold and dried. A further optional substrate layer is applied to the backing or basement layer. A flow chart of an exemplary method of forming a microstructure array is shown in
Filling the cavities of the mold with the liquid formulations has been a challenge. In casting a solution on the mold, it is commonly desired to avoid the presence of bubbles of air between the casting solution and the mold during casting. Due to the shape required to produce a sharp tip and/or the surface properties of the mold, bubbles often form/are trapped between the formulation and the mold surface as the liquid casting solution is moved into the mold cavities. This may be more prevalent at the deepest portion of the mold cavities. Air bubbles may be trapped especially at the tip of the cavities. If the formulation does not fill the cavities, the resulting microstructures may not have the desired shape including gaps and/or not have the required sharp tip. The shape of the meniscus for the casting solution in the cavity and/or the extent of filling the cavity is dependent upon the contact angle behavior of the casting solution on the mold surface.
Various approaches have been used to minimize or remove air bubbles in the cavities. The mold may be treated prior to dispensing the casting solution to improve dispensing of the casting solution and/or to avoid or reduce the presence of air bubbles. The mold itself, or portions of it, may be subject to surface treatments which make it easier for the solution to wet the mold surface. Suitable treatments are known in the art and described, for example, in U.S. Patent Publication No. 2008/0269685, which is incorporated herein in its entirety. U.S. Patent Publication No. 2008/0269685 describes applying a vacuum over the cavities while the casting solution is dispensed into the mold cavities. When the vacuum is removed, the higher pressure over the liquid film will shrink the bubble in the cavity and push the casting solution into the cavity.
A further approach is described, for example, in U.S. Patent Publication No. 2014/0272101, which is incorporated herein in its entirety, where the mold with the casting solution is pressurized to move the solution into the cavities. The pressurization shrinks the size of the air bubble as expected by Boyle's Law. For example, an air bubble that has a volume of 1 μL at 1 atmosphere will have an approximate volume of 0.2 μL at 50 psig (5 atm). As the bubble size shrinks, further casting solution fills the cavity further into the cavity and the area/volume ratio of the air bubble decreases allowing for a corresponding decrease in time required for the air to diffuse into the mold. While pressurization works well for a batch processes it is difficult and not economical to scale in order while maintaining high drug utilization. The leak pressure for a scaled batch process is an order of magnitude lower than the pressure necessary to effectively reduce air bubble size.
In a further approach described, for example, in U.S. Patent Publication No. 2008/0269685, a vacuum is applied to the mold after a casting solution is applied over the cavities in the mold. The vacuum causes the air bubbles in the cavities to expand and increase the force pushing the bubbles up through the casting solution. The air bubbles rise to the surface of the casting solution. Drying must be modulated to allow the air bubbles to rise completely through the casting solution or air voids will be formed within the microstructures as the solution dries.
Yet a further approach uses a soluble gas such as carbon dioxide (CO2) to move the casting solution into or further into the cavities as described in U.S. Patent Publication No. 2014/0272101. The soluble gas displaces air in the cavities. Because the solubility and diffusivity of the soluble gas into the mold is significantly greater than air, the time required for any gas bubbles to permeate into the mold is reduced. While the high solubility and diffusivity of soluble gases such CO2 are effective to reduce bubble size, some casting solution formulations are not compatible with the soluble gas. In particular, the soluble gas may adversely affect the pH or other characteristic of the casting solution and/or mold. For example, CO2 gas may lower the pH of the casting solution, which presents the risk that the active agent may precipitate out of the solution. Thus, the effectiveness of using a soluble gas such as CO2 may therefore be dependent upon the formulation of the casting solution. A further method of reducing, removing, or preventing air bubbles that is independent or relatively independent of the casting is therefore desirable.
In a preferred embodiment, a rough or low vacuum is applied to the mold prior to dispensing the casting solution on or in the mold to reduce the size of any air bubbles by removing the air in the cavities prior to dispensing the casting solution on or into the mold. Rather than applying a vacuum after the casting solution is dispensed onto or into the mold, the vacuum is applied prior to dispensing the casting solution to remove at least some of the air in the cavities prior to fill. In a preferred embodiment, a rough or low vacuum is applied to the mold prior to dispensing the casting solution. A rough or low vacuum is typically a vacuum that is slightly below atmospheric pressure. For convenience, the terms “rough vacuum”, “low vacuum” and “medium” vacuum are used interchangeably hereafter. By “applied” with reference to a vacuum, it is typically intended that the mold is placed into and/or passed through a chamber or other container having the desired partial pressure. In embodiments, a low vacuum has a pressure of less than atmospheric (760 Torr). In embodiments, the low vacuum has a pressure range of less than about 760 to about 25 Torr. In embodiments a vacuum of about 750-25, about 700-25, about 600-25, about 500-25, about 400-25, about 300-25, about 200-25, about 150-25, about 100-25, about 760-100, about 750-100, about 700-100, about 600-100, about 500-100, about 400-100, about 300-100, about 200-100, about 760-150, about 750-150, about 700-150, about 600-150, about 500-150, about 400-150, about 300-150, about 200-150, about 100-150, about 760-200, about 750-200, about 700-200, about 600-200, about 500-200, about 400-200, about 300-200, about 760-300, about 750-300, about 700-300, about 600-300, about 500-300, about 400-300, about 760-400, about 750-400, about 700-400, about 600-400, about 500-400, about 760-500, about 750-500, about 700-500, about 600-500, about 760-600, about 750-600, or about 700-600 Torr is applied to the mold prior to dispensing the casting solution.
In embodiments, all or substantially all of the air in the cavities is removed by application of a low vacuum prior to dispensing the casting solution. The reduction in air in the cavities results in a corresponding decrease in the volume of air bubbles trapped between the casting solution and the mold as the cavities are filled. As shown in
It will be appreciated that the step of applying a low vacuum prior to dispensing the casting solution may be combined with one or more known methods of reducing or eliminating air bubbles. In one example, the use of a soluble gas may be combined with application of low pressure to further reduce air bubbles. As seen in
After the low vacuum is applied, a casting solution or formulation 22 is dispensed onto the mold and/or into the mold cavities 18. It will be appreciated that the casting solution or formulation may be dispensed onto the mold and/or into the mold cavities while the low vacuum is applied. Where the solution is cast on the mold, the solution is moved into the cavities by any suitable means. In one embodiment, the mold surface with solution thereon is covered to spread the solution or formulation on the mold and at least partially into the cavities. In other embodiments, the solution is spread on the mold without covering. The cavities are filled with the casting solution.
In one embodiment, the mold is pressurized, with or without a cover, to move the solution into or further into the cavities of the mold. Pressurization may be accomplished by placing the mold with the casting solution into a pressure vessel as known in the art. Pressurization may involve a pressure of at least about 3 psi, about 5 psi, about 10 psi, about 14.7 psi, about 20 psi, or about 50 psi above atmospheric. In other embodiments, pressurization involves a pressure of at least about 3-50 psi above atmospheric. In other embodiments, pressurization involves a pressure of at least about 3-40 psi, about 3-30 psi, about 3-20 psi, about 3-14.7 psi, about 3-10 psi, about 3-5 psi, about 5-50 psi, about 5-30 psi, about 5-20 psi, about 5-14.7 psi, about 5-10 psi, about 10-50 psi, about 10-30 psi, about 10-20 psi, about 10-14.7 psi, about 20-50 psi, about 20-30 psi, or about 30-40 psi above atmospheric. Excess solution may be wiped or otherwise removed from the mold surface by any suitable means.
The mold with liquid casting solution is then dried using a single or multiple drying steps. Multiple and/or controlled drying steps are used to remove excess solvent and/or dry the microprojections. In one embodiment, the mold with liquid casting solution is dried at a temperature of about 5-50° C. for about 30 minutes to about 2 hours. It will be appreciated that the mold with liquid casting solution may be dried for any appropriate period of time to remove all or substantially all of the casting solution solvent(s). Drying may involve placing the mold with solution in an oven or other temperature controlled chamber. In another embodiment, a two-step primary drying method is used. The first step in a two-step drying method uses a slow drying method in which the mold with casting solution is dried under controlled humidity. Where the drying step involves controlling humidity, the mold is in dried in a chamber or section where humidity in the chamber is controlled from at least about 10% to about 95% relative humidity (RH). The mold with casting solution is initially dried for about 5 minutes to about an hour at a temperature of about 5-50° C. The second step involves drying without humidity control. In non-limiting embodiments, the second step involves drying the mold and casting solution/formulation at a temperature of about 5-50° C. for about 20-120 minutes or more. In another embodiment, the casting solution is dried in a chamber having a controlled partial pressure of the evaporate. Further, the mold with the liquid casting solution may be dried from beneath, under or below the mold. It will be appreciated that the casting solution may be dried from substantially beneath, under or below the mold. Specific embodiments of drying times, humidity, and/or drying conditions are disclosed in U.S. Patent Publication Nos. 2008/0269685 and 2014/0272101, which are incorporated herein by reference.
In one embodiment, an optional backing layer, base layer, or basement layer is further cast on the mold. A liquid backing formulation is dispensed on the mold or into the cavities. The liquid backing formulation is typically prepared by dissolving or suspending one or more polymers in a suitable solvent. In a preferred embodiment, the one or more polymers are biocompatible. Typically, but not always, the polymers are non-biodegradable. In another embodiment, the backing formulation may comprise one or more biodegradable and/or non-biodegradable polymers. Suitable biodegradable polymers are described above. Suitable non-biodegradable polymers are known in the art and include, but are not limited to, amphiphilic polyurethanes, polyether polyurethane (PEU), polyetheretherketone (PEEK), polylactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyethylene terephthalate, polycarbonate, acrylic polymers such as those sold under the trade name Eudragit®, polyvinylpyrrolidones (PVP), polyamide-imide (PAI), and/or co-polymers thereof. Further suitable polymers are described in U.S. Pat. No. 7,785,301, which is incorporated herein in its entirety. The backing formulation may include one or more excipients as described above for the active agent casting solution. In another embodiment, the backing layer is an adhesive layer. One suitable adhesive is the Dymax® 1187-M UV medical device adhesive. It will be appreciated that any biocompatible adhesive is suitable for use with, in and/or as the backing layer. This layer may also be a nonwoven or porous film double coated with pressure sensitive adhesive. Liquid backing formulations may be moved into the cavities by the same or similar methods as for the active agent casting solution.
Where a liquid backing layer formulation is used, the solvent of the backing layer formulation is removed by a drying process such that the resulting array has a backing layer with a plurality of microstructures extending at an angle from the backing layer. The drying conditions for drying the backing layer should be controlled so that the backing layer solvent can be removed effectively without affecting the stability of an active agent and/or to properly form (e.g. uniform) the backing layer. It will be appreciated that the conditions and methods for drying the active agent formulations as described above may be used for drying the backing layer formulations. In one embodiment, the mold is placed into a compressed dry air (CDA) box under controlled air flow and then placed in an oven at about 5-50° C. In further embodiments, the mold is placed in the oven at a temperature of about 5-50° C. In embodiments, the temperature of the CDA and/or oven is about 5° C., about 10° C., about 20° C., about 30° C., about 40° C., about 45° C., or about 50° C. In embodiments, the temperature of the CDA and/or oven is about 5-45° C., 5-40° C., 5-30° C., 5-20° C., 5-15° C., 5-10° C., 10-50° C., 10-45° C., 10-40° C., 10-30° C., 10-20° C., 10-15° C., 15-50° C., 15-45° C., 15-40° C., 15-30° C., 15-20° C., 20-50° C., 20-45° C., 20-40° C., 20-30° C., 30-50° C., 30-45° C., 30-40° C., 30-45° C., 40-50° C., 40-45° C., or 45-50° C. In embodiments, the oven uses convection, conduction, or radiation for drying. In another embodiment, the mold is placed in an oven at about 5-50° C. without prior time in a CDA box. In embodiments, the mold is placed in the CDA and/or oven for at least about 0-120 minutes, about 30-120 minutes, about 30-90 minutes, about 30-60 minutes, about 30-45 minutes, about 45-120 minutes, about 45-90 minutes, about 45-60 minutes, about 60-120 minutes, about 60-90 minutes, about 90-120 minutes, or longer. Residual solvents in the backing layer can be measured to determine the effectiveness of solvent removal under different drying conditions. The backing layer connects and/or supports the microprojection tips.
The backing layer with attached microstructures is demolded as described further below and undergoes an optional final drying step to form the microstructure array (MSA). Before or after the microprojection array is removed from the mold a final drying step may be performed. This final drying step may be performed under vacuum. The final drying may be at room temperature or at an elevated temperature. In embodiments, the final drying is at about 5-50° C. In embodiments, the final drying is at about 5° C., at about 10° C., at about 20° C., at about 25° C., at about 35° C., at about 40° C., at about 45° C., or at about 50° C. Further suitable temperatures and ranges are described above with reference to drying the backing layer. In embodiments, the final drying is from about 1-24 hours or longer, from about 4-20 hours, from about 6-10 hours, from about 8-16 hours, from about 8-12 hours, from about 8-10 hours, from about 10-12 hours, from about 10-16 hours, from about 12-16 hours or longer. In other embodiments, the final drying step is overnight. It will be appreciated that the MSA may be demolded prior to undergoing the final drying step.
Before or after the optional final drying step, the microprojection arrays may further and optionally be positioned on a base or substrate. The substrate may be in addition to or instead of a backing layer. The microprojections may be attached to the substrate by any suitable means. In one, non-limiting embodiment, the microstructures are attached to the substrate using an adhesive. Suitable adhesives include, but are not limited to, acrylic adhesives, acrylate adhesives, pressure sensitive adhesives, double-sided adhesive tape, double sided adhesive coated nonwoven or porous film, and UV curable adhesives. One exemplary double-sided tape is the #1513 double-coated medical tape available from 3M. One exemplary, but non-limiting, UV curable adhesive is the 1187-M UV light-curable adhesive available from Dymax®. It will be appreciated that any medical device adhesive known in the art would be suitable. In one embodiment, the substrate is a breathable nonwoven pressure sensitive adhesive. The substrate is placed on the backing layer where present or a proximal surface of the microprojections. The substrate is adhered or attached to the microprojections. In another embodiment, the substrate is a UV cured adhesive in a polycarbonate film. The UV adhesive is dispensed on the top of the backing layer or the proximal surface of the microprojections, covered with a polycarbonate (PC) film to spread the adhesive and cured using a UV Fusion system. In one embodiment a UV curing dose is about 1.6 J/cm2. After the substrate is attached or adhered to the microprojections, the microprojection array is removed from the mold. It will be appreciated where the array includes a backing layer the substrate is attached or adhered to the backing layer as described above for the microstructures.
Cast microprojection arrays are removed from the mold by any suitable means. In one embodiment, the microprojection array is removed from the mold by using a de-mold tool. A double-sided adhesive is placed on the back of microprojection array with one side for adhering to the array and the other side for adhering to the de-mold tool. The array is removed from the mold by gently rolling the de-mold tool over the adhesive on the back of the array with a slight rolling angle, such as about 1-90 degrees. The microprojection array is then gently peeled off from the de-mold tool. The arrays may be demolded after drying the backing layer or after a final drying step.
After the microprojection array is removed from the mold, it may be cut to an appropriate size and/or shape. In one embodiment, the microprojection array is die cut with an 11 or 16 mm punch.
General features of microstructure arrays suitable for use in the instant arrays and methods are described in detail in U.S. Patent Publication No. 2008/0269685, U.S. Patent Publication No. 2011/0006458, and U.S. Patent Publication No. 2011/0276028, the entire contents of which are explicitly incorporated herein by reference.
The microstructure arrays are preferably stable both during the fabrication process as described above and have a stable shelf life. Short-term stability of the arrays may be evaluated by storing the arrays at various temperatures and/or humidities and analyzing monomer content, composition purity, and deamidation of proteins by SEC-HPLC, RP-HPLC, and IEX-HPLC. The liquid casting solution or formulation is preferably stable during the fabrication process, which typically lasts a few hours. Preferably, the liquid casting solution is stable for a period of 30 minutes to 6 hours. In non-limiting embodiments, the liquid casting solution is stable for a period of at least from 30 minutes to 1 hour, from 30 minutes to 2 hours, from 30 minutes to 3 hours, from 30 minutes to 4 hours, from 30 minutes to 5 hours, from 1-6 hours, from 1-5 hours, from 1-4 hours, from 1-3 hours, from 1-2 hours, from 2-6 hours, from 2-5 hours, from 2-4 hours, from 2-3 hours, from 3-6 hours, from 3-5 hours, from 3-4 hours, from 4-6 hours, from 4-5 hours, or from 5-6 hours. In specific, but not limiting embodiments, the liquid casting solution is stable for at least about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, or longer. The microstructure arrays are preferably stable for at least about one day when stored at about room temperature (e.g. about 25° C.). In other embodiments, the arrays are preferably stable for at least about 1 week when stored at about 5° C. In other embodiments, the arrays are stable when stored at an elevated temperature (e.g. about 40° C.) for at least about 1-12 weeks, about 1-16 weeks, or about 1-32 weeks. In other embodiments, the arrays are stable when stored at about 5° C. for at least about 1-52 weeks or 1-156 weeks. It will be appreciated that the shelf-life may vary depending on the storage temperature. In embodiments, the arrays are stable when stored at about 5° C. for at least about 1-156 weeks, about 1-12 weeks, about 1-2 weeks, about 1-3 weeks, about 1-4 weeks, about 1-5 weeks, about 2-6 weeks, about 2-5 weeks, about 2-4 weeks, about 2-3 weeks, about 3-6 weeks, about 3-5 weeks, about 3-4 weeks, about 4-6 weeks, about 4-5 weeks, or about 5-6 weeks. In embodiments, the arrays are stable when stored at about 40° C. for at least about 1-26 weeks, about 1-12 weeks, about 1-2 weeks, about 1-3 weeks, about 1-4 weeks, about 1-5 weeks, about 2-6 weeks, about 2-5 weeks, about 2-4 weeks, about 2-3 weeks, about 3-6 weeks, about 3-5 weeks, about 3-4 weeks, about 4-6 weeks, about 4-5 weeks, or about 5-6 weeks. In other embodiments, the arrays are stable when stored at about 25° C. for at least about 1-14 days. In further embodiments, the arrays are stable when stored at about 25° C. for at least about 1-12 weeks, about 1-16 weeks, about 1-104 weeks, or about 1-156 weeks. In specific, but not limiting, embodiments, the arrays are stable when stored at about 5° C. for at least about 5 days, at least about 1 week, at least about 2 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, or longer. In embodiments, the arrays are stable when stored at about 25° C. for at least about 1-2 days, about 1-5 days, about 1-7 days, about 1-10 days, about 2-5 days, about 2-7 days, about 2-10 days, about 2-14 days, about 3-5 days, about 3-7 days, about 3-10 days, about 3-14 days, about 5-14 days, about 5-10 days, about 5-14 days, or about 10-14 days. In specific, but not limiting, embodiments, the arrays are stable when stored at about 25° C. for at least about 12 hours, at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about one week, or longer. Stability is typically monitored by measuring the purity of the active agent in the array after storage as compared to an array before storage (time=0). In embodiments, the array has a purity of at least about 80-100%, about 85-100%, about 90-100%, about 95-100%, about 80-95%, about 85-95%, about 90-95% about 80-90%, about 85-90% or about 80-85% after storage. In non-limiting embodiments, the array has a purity of at least about 80%, about 85%, about 90%, about 92%, about 93%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% after storage.
Where the active agent is a protein, Methionine-oxidation (Met-oxidation) is preferably less than or equal to 1-20% after storage for about 1-6 weeks at about 5° C.-40° C. In embodiments Met-oxidation is less than about 1-10%, about 1-5%, about 1-6%, about 2-3%, about 2-4%, about 2-5%, 2-6%, about 3-5%, or about 3-6%. In specific, but not limiting, embodiments, Met-oxidation is less than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, or about 10%.
The microstructure arrays should have sufficient mechanical strength to at least partially penetrate the stratum corneum or other membrane surface of a subject. It will be appreciated that different mechanical strength will be required for application at different sites. One method for assessing mechanical strength is a skin-penetration efficiency (SPE) study as described U.S. Patent Publication No. 2014/0272101. Preferably, the arrays have a SPE of at least about 50-100%. In other embodiments, the arrays have a SPE of at least about 50-80%, about 50-85%, about 50-90%, about 50-95%, about 60-80%, about 60-85%, about 60-90%, about 60-95%, about 60-100%, about 75-80%, about 75-85%, about 75-90%, about 75-95%, about 75-100%, about 80-85%, about 80-90%, about 80-95%, about 80-100%, about 90-95%, and about 90-100%. In specific, non-limiting, embodiments, the arrays have a SPE of at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, and 100%.
Preferably, at least about 50-100% of the active agent is delivered by the MSAs described herein. Delivery efficiency may be determined by preparing the MSA and applying the MSA in vivo or in vitro. In embodiments, the MSA has a delivery efficiency of at least about 50-60%, about 50-70%, about 50-75%, about 50-80%, about 50-90%, about 50-95%, about 50-99%, about 60-70%, about 60-75%, about 60-80%, about 60-90%, about 60-95%, about 60-99%, about 70-75%, about 70-80%, about 70-90%, about 70-95%, about 70-99%, about 75-80%, about 75-90%, about 75-95%, about 75-99%, about 80-90%, about 80-95%, about 80-99%, about 90-95%, about 90-99%, or about 95-99%.
The methods, kits, microstructure arrays and related devices described herein may be used for treating any condition. It will be appreciated that the microstructure arrays may be used with any appropriate applicator including the applicator described in U.S. Publication No. 2011/0276027, as well as those described in U.S. Publication No. 2014/0276580 and 2014/0276366, each of which are incorporated herein in their entirety.
The following examples are illustrative in nature and are in no way intended to be limiting. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. and pressure is at or near atmospheric.
A silicone mold comprising a plurality of microstructure cavities is purged with carbon dioxide (CO2). The mold is placed in a vacuum of less than 1 atm. About 90 μL of a liquid formulation comprising an active agent is dispensed onto the mold from a reservoir using a syringe or fountain type reservoir. The mold containing the formulation is pressurized for 1 minute at about 50 psi. The mold surface is then wiped to remove excess formulation from the mold surface.
Depending on the physiochemical properties of the liquid formulation (viscosity, solid content, surface interaction between formulation and mold, etc.), the formulation is dried using either one or two primary drying steps. The one step primary drying comprises directly placing the mold comprising the liquid formulation in an incubator oven at 32° C. for about 30 minutes to remove solvents.
In the two step primary drying, a slow drying step is followed by a second drying step. The mold with the liquid formulation is placed in a chamber where the humidity is controlled to about 50% to 90% relative humidity (RH), at room temperature for about 5 to 30 minutes. The air convection in the chamber may also be controlled. The mold with formulation is then incubated for about 30 minutes in an oven at about 30° C. to 35° C.
A backing layer liquid formulation is then dispensed onto the mold surface from a second reservoir. The backing layer formulation is moved into the mold cavities to contact the dried active agent formulation. The backing layer formulation dried to remove the solvent. The mold with the backing layer formulation is placed into a compressed dry air box for about 30 minutes with controlled air flow, and then placed in a convection oven at about 40° C. to 50° C. for about 90 minutes. The backing layer formulation contacts the drug formulation to connect and support the drug formulation, which becomes the distal tip or portion of the microstructures.
A breathable, nonwoven pressure sensitive adhesive is placed on the dried backing layer to form a substrate layer. Alternatively, a UV adhesive is dispensed on the top of the backing layer, covered with 5 ml polycarbonate (PC) film to spread the adhesive, and then cured using a UV Fusion system. The UV curing dose is about 1.6 J/cm2.
The microstructure array comprising the drug-in-tip (DIT) layer comprising the active agent, the backing layer, and the substrate is demolded or removed from the mold. The array is die cut with an 11 mm or 16 mm punch. The microstructure array is dried under vacuum (˜0.05 torr) at room temperature (˜35° C.) overnight.
(a) dissolving or suspending at least one therapeutic agent in a first solvent to form a therapeutic agent solution or suspension;
(b) dissolving at least one polymer in a second solvent to form a polymer matrix solution or suspension;
(c) mixing the therapeutic agent solution or suspension and the polymer solution or suspension to form a polymer matrix solution or suspension;
(d) applying a low vacuum to a mold having an array of microstructure cavities;
(e) dispensing the polymer matrix solution or suspension on the mold;
(f) filling the microstructure cavities in the mold;
(g) drying the solution or suspension to form the array of microstructures.
after step (f), removing excess polymer matrix solution or suspension on the mold surface.
dispensing a basement or backing layer formulation on the mold surface; and drying the basement or backing layer formulation.
affixing the basement or backing layer to a substrate.
demolding the microstructure array.
demolding the microstructure array after drying the basement or backing layer.
dissolving at least one of a sugar, a surfactant, or an antioxidant in at least one of the first or the second solvent.
dissolving a sugar in the polymer matrix solution or suspension after step (b).
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true spirit and scope.
All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not necessarily to the text of this application, in particular the claims of this application, in which instance, the definitions provided herein are meant to supersede.
This application claims the benefit of U.S. Provisional Application No. 62/186,310, filed Jun. 29, 2015, which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1554510 | Kirby | Sep 1925 | A |
| 1770632 | Smith | Jul 1930 | A |
| 2046240 | Bayley | Jun 1936 | A |
| 2434407 | George | Jan 1948 | A |
| 3675766 | Rosenthal | Jul 1972 | A |
| 3704194 | Harrier et al. | Nov 1972 | A |
| 3814097 | Ganderton et al. | Jun 1974 | A |
| 3873255 | Kalwaites | Mar 1975 | A |
| 3918449 | Pistor | Nov 1975 | A |
| 3964482 | Gerstel et al. | Jun 1976 | A |
| 4055029 | Kalbow | Oct 1977 | A |
| 4117841 | Perrotta et al. | Oct 1978 | A |
| 4151240 | Lucas et al. | Apr 1979 | A |
| 4180232 | Hardigg | Dec 1979 | A |
| 4342314 | Radel et al. | Aug 1982 | A |
| 4381963 | Goldstein et al. | May 1983 | A |
| 4395215 | Bishop | Jul 1983 | A |
| 4402696 | Gulko | Sep 1983 | A |
| 4460368 | Allison et al. | Jul 1984 | A |
| 4460370 | Allison et al. | Jul 1984 | A |
| 4463045 | Ahr et al. | Jul 1984 | A |
| 4509908 | Mullane, Jr. | Apr 1985 | A |
| 4515168 | Chester et al. | May 1985 | A |
| 4556441 | Faasse, Jr. | Dec 1985 | A |
| 4585991 | Reid et al. | Apr 1986 | A |
| 4597961 | Etscorn | Jul 1986 | A |
| 4609518 | Curro et al. | Sep 1986 | A |
| 4630603 | Greenway | Dec 1986 | A |
| 4660721 | Mykleby | Apr 1987 | A |
| 4695422 | Curro et al. | Sep 1987 | A |
| 4743234 | Leopoldi et al. | May 1988 | A |
| 4743249 | Loveland | May 1988 | A |
| 4784737 | Ray et al. | Nov 1988 | A |
| 4812305 | Vocal | Mar 1989 | A |
| 4837049 | Byers et al. | Jun 1989 | A |
| 4846821 | Lyons et al. | Jul 1989 | A |
| 4904475 | Gale et al. | Feb 1990 | A |
| 4996159 | Glaser | Feb 1991 | A |
| 5051259 | Olsen et al. | Sep 1991 | A |
| 5061258 | Martz | Oct 1991 | A |
| 5134079 | Cusack et al. | Jul 1992 | A |
| 5139029 | Fishman et al. | Aug 1992 | A |
| 5156591 | Gross et al. | Oct 1992 | A |
| 5158073 | Bukowski | Oct 1992 | A |
| 5160315 | Heinecke et al. | Nov 1992 | A |
| 5162043 | Lew et al. | Nov 1992 | A |
| 5163918 | Righi et al. | Nov 1992 | A |
| 5190558 | Ito | Mar 1993 | A |
| 5198192 | Saito et al. | Mar 1993 | A |
| 5215088 | Normann et al. | Jun 1993 | A |
| 5244677 | Kreckel et al. | Sep 1993 | A |
| 5244711 | Drelich et al. | Sep 1993 | A |
| 5250023 | Lee et al. | Oct 1993 | A |
| 5250067 | Gelfer et al. | Oct 1993 | A |
| 5252279 | Gore et al. | Oct 1993 | A |
| 5256360 | Li | Oct 1993 | A |
| 5279544 | Gross et al. | Jan 1994 | A |
| 5308625 | Wong et al. | May 1994 | A |
| 5318557 | Gross | Jun 1994 | A |
| 5320600 | Lambert | Jun 1994 | A |
| 5330452 | Zook | Jul 1994 | A |
| 5362307 | Guy et al. | Nov 1994 | A |
| 5383512 | Jarvis | Jan 1995 | A |
| 5457041 | Ginaven et al. | Oct 1995 | A |
| 5462743 | Turner et al. | Oct 1995 | A |
| 5476443 | Cartmell et al. | Dec 1995 | A |
| 5487726 | Rabenau et al. | Jan 1996 | A |
| 5496304 | Chasan | Mar 1996 | A |
| 5498235 | Flower | Mar 1996 | A |
| 5503843 | Santus et al. | Apr 1996 | A |
| 5512219 | Rowland et al. | Apr 1996 | A |
| 5520629 | Heinecke et al. | May 1996 | A |
| 5527287 | Miskinyar | Jun 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5531675 | Yoo | Jul 1996 | A |
| 5531855 | Heinecke et al. | Jul 1996 | A |
| 5536263 | Rolf et al. | Jul 1996 | A |
| 5551953 | Lattin et al. | Sep 1996 | A |
| 5567376 | Turi et al. | Oct 1996 | A |
| 5569469 | Lovrecich | Oct 1996 | A |
| 5591123 | Sibalis et al. | Jan 1997 | A |
| 5591139 | Lin et al. | Jan 1997 | A |
| 5611806 | Jang | Mar 1997 | A |
| 5645977 | Wu et al. | Jul 1997 | A |
| 5658515 | Lee et al. | Aug 1997 | A |
| 5662127 | De Vaughn | Sep 1997 | A |
| 5676850 | Reed et al. | Oct 1997 | A |
| 5681580 | Jang et al. | Oct 1997 | A |
| 5697901 | Eriksson | Dec 1997 | A |
| 5704520 | Gross | Jan 1998 | A |
| 5711761 | Untereker et al. | Jan 1998 | A |
| 5728089 | Lal et al. | Mar 1998 | A |
| 5730714 | Guy et al. | Mar 1998 | A |
| 5730721 | Hyatt et al. | Mar 1998 | A |
| 5735273 | Kurnik et al. | Apr 1998 | A |
| 5738642 | Heinecke et al. | Apr 1998 | A |
| 5756117 | D'Angelo et al. | May 1998 | A |
| 5771890 | Tamada | Jun 1998 | A |
| 5788983 | Chien et al. | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5814020 | Gross | Sep 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5827183 | Kurnik et al. | Oct 1998 | A |
| 5843114 | Jang | Dec 1998 | A |
| 5848985 | Muroki | Dec 1998 | A |
| 5848990 | Cirelli et al. | Dec 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851549 | Svec | Dec 1998 | A |
| 5855801 | Lin et al. | Jan 1999 | A |
| 5868244 | Ivanov et al. | Feb 1999 | A |
| 5873849 | Bernard | Feb 1999 | A |
| 5879326 | Godshall et al. | Mar 1999 | A |
| 5900252 | Calanchi et al. | May 1999 | A |
| 5932240 | D'Angelo et al. | Aug 1999 | A |
| 5938684 | Lynch et al. | Aug 1999 | A |
| 5948488 | Marecki et al. | Sep 1999 | A |
| 5962011 | Devillez et al. | Oct 1999 | A |
| 5964729 | Choi et al. | Oct 1999 | A |
| 5983136 | Kamen | Nov 1999 | A |
| 5987989 | Yamamoto et al. | Nov 1999 | A |
| 5997549 | Sauceda et al. | Dec 1999 | A |
| 5997986 | Turi et al. | Dec 1999 | A |
| 6014584 | Hofmann et al. | Jan 2000 | A |
| 6023629 | Tamada | Feb 2000 | A |
| 6024553 | Shimalla | Feb 2000 | A |
| 6036659 | Ray et al. | Mar 2000 | A |
| 6038465 | Melton, Jr. | Mar 2000 | A |
| 6038485 | Axelgaard | Mar 2000 | A |
| 6047208 | Flower | Apr 2000 | A |
| 6050988 | Zuck | Apr 2000 | A |
| 6055453 | Hofmann et al. | Apr 2000 | A |
| 6080172 | Fujiwara et al. | Jun 2000 | A |
| 6083196 | Trautman et al. | Jul 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6106751 | Talbot et al. | Aug 2000 | A |
| 6120792 | Juni | Sep 2000 | A |
| 6129696 | Sibalis | Oct 2000 | A |
| 6132449 | Lum et al. | Oct 2000 | A |
| 6132755 | Eicher et al. | Oct 2000 | A |
| 6135990 | Heller et al. | Oct 2000 | A |
| 6136008 | Becker et al. | Oct 2000 | A |
| 6156336 | Bracht | Dec 2000 | A |
| 6169224 | Heinecke et al. | Jan 2001 | B1 |
| 6181964 | Hofmann et al. | Jan 2001 | B1 |
| 6183434 | Eppstein | Feb 2001 | B1 |
| 6183770 | Muchin et al. | Feb 2001 | B1 |
| 6187210 | Lebouitz et al. | Feb 2001 | B1 |
| 6216034 | Hofmann et al. | Apr 2001 | B1 |
| 6219574 | Cormier et al. | Apr 2001 | B1 |
| 6230051 | Cormier et al. | May 2001 | B1 |
| 6241701 | Hofmann | Jun 2001 | B1 |
| 6248120 | Wyszogrodzki | Jun 2001 | B1 |
| 6256533 | Yuzhakov et al. | Jul 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6312612 | Sherman et al. | Nov 2001 | B1 |
| 6322808 | Trautman et al. | Nov 2001 | B1 |
| 6334856 | Allen et al. | Jan 2002 | B1 |
| 6355054 | Neuberger | Mar 2002 | B1 |
| 6375627 | Mauze et al. | Apr 2002 | B1 |
| 6375870 | Visovsky et al. | Apr 2002 | B1 |
| 6375978 | Kleiner et al. | Apr 2002 | B1 |
| 6379324 | Gartstein et al. | Apr 2002 | B1 |
| 6440096 | Lastovich et al. | Aug 2002 | B1 |
| 6451240 | Sherman et al. | Sep 2002 | B1 |
| 6471903 | Sherman et al. | Oct 2002 | B2 |
| 6476288 | Van Rijswijck et al. | Nov 2002 | B1 |
| 6485470 | Hostettler et al. | Nov 2002 | B2 |
| 6494830 | Wessel | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6508947 | Gulvin et al. | Jan 2003 | B2 |
| 6511463 | Wood et al. | Jan 2003 | B1 |
| 6512626 | Schmidt | Jan 2003 | B1 |
| 6516223 | Hofmann | Feb 2003 | B2 |
| 6532386 | Sun et al. | Mar 2003 | B2 |
| 6533884 | Mallik | Mar 2003 | B1 |
| 6537242 | Palmer | Mar 2003 | B1 |
| 6537264 | Cormier et al. | Mar 2003 | B1 |
| 6558361 | Yeshurun | May 2003 | B1 |
| 6562014 | Lin et al. | May 2003 | B2 |
| 6565532 | Yuzhakov et al. | May 2003 | B1 |
| 6585742 | Stough | Jul 2003 | B2 |
| 6589202 | Powell | Jul 2003 | B1 |
| 6591124 | Sherman et al. | Jul 2003 | B2 |
| 6591133 | Joshi | Jul 2003 | B1 |
| 6603987 | Whitson | Aug 2003 | B2 |
| 6610463 | Ohkura et al. | Aug 2003 | B1 |
| 6611706 | Avrahami et al. | Aug 2003 | B2 |
| 6611707 | Prausnitz et al. | Aug 2003 | B1 |
| 6623457 | Rosenberg | Sep 2003 | B1 |
| 6629949 | Douglas | Oct 2003 | B1 |
| 6652478 | Gartstein et al. | Nov 2003 | B1 |
| 6656147 | Gertsek et al. | Dec 2003 | B1 |
| 6663820 | Arias et al. | Dec 2003 | B2 |
| 6685682 | Heinecke et al. | Feb 2004 | B1 |
| 6689103 | Palasis | Feb 2004 | B1 |
| 6691752 | DiSabatino | Feb 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6767341 | Cho | Jul 2004 | B2 |
| 6770480 | Canham | Aug 2004 | B1 |
| 6778853 | Heller et al. | Aug 2004 | B1 |
| 6780171 | Gabel et al. | Aug 2004 | B2 |
| 6808506 | Lastovich et al. | Oct 2004 | B2 |
| 6821281 | Sherman et al. | Nov 2004 | B2 |
| 6835184 | Sage et al. | Dec 2004 | B1 |
| 6855131 | Trautman et al. | Feb 2005 | B2 |
| 6881203 | Delmore et al. | Apr 2005 | B2 |
| 6931277 | Yuzhakov et al. | Aug 2005 | B1 |
| 6945952 | Kwon | Sep 2005 | B2 |
| 6960193 | Rosenberg | Nov 2005 | B2 |
| 6980855 | Cho et al. | Dec 2005 | B2 |
| 6991809 | Anderson | Jan 2006 | B2 |
| 7011844 | Gale et al. | Mar 2006 | B2 |
| 7048723 | Frazier et al. | May 2006 | B1 |
| 7062317 | Avrahami et al. | Jun 2006 | B2 |
| 7087035 | Trautman et al. | Aug 2006 | B2 |
| 7097631 | Trautman et al. | Aug 2006 | B2 |
| 7108681 | Gartstein et al. | Sep 2006 | B2 |
| 7115108 | Wilkinson et al. | Oct 2006 | B2 |
| 7128730 | Marano-Ford et al. | Oct 2006 | B2 |
| 7131960 | Trautman et al. | Nov 2006 | B2 |
| 7131987 | Sherman et al. | Nov 2006 | B2 |
| 7166086 | Haider et al. | Jan 2007 | B2 |
| 7184826 | Cormier et al. | Feb 2007 | B2 |
| 7186235 | Martin et al. | Mar 2007 | B2 |
| 7226439 | Prausnitz et al. | Jun 2007 | B2 |
| 7332339 | Canham | Feb 2008 | B2 |
| 7412284 | Hofmann | Aug 2008 | B2 |
| 7416541 | Yuzhakov et al. | Aug 2008 | B2 |
| 7419481 | Trautman et al. | Sep 2008 | B2 |
| 7572405 | Sherman et al. | Aug 2009 | B2 |
| 7578954 | Gartstein et al. | Aug 2009 | B2 |
| 7578985 | Aderhold et al. | Aug 2009 | B2 |
| 7611481 | Cleary et al. | Nov 2009 | B2 |
| 7658728 | Yuzhakov | Feb 2010 | B2 |
| 7678777 | Yasuda et al. | Mar 2010 | B2 |
| 7763203 | Arias et al. | Jul 2010 | B2 |
| 7785301 | Yuzhakov | Aug 2010 | B2 |
| 7789733 | Sugimura | Sep 2010 | B2 |
| 7798987 | Trautman et al. | Sep 2010 | B2 |
| 7828827 | Gartstein et al. | Nov 2010 | B2 |
| 7846488 | Johnson | Dec 2010 | B2 |
| 7914480 | Cleary et al. | Mar 2011 | B2 |
| 8057842 | Choi et al. | Nov 2011 | B2 |
| 8062573 | Kwon | Nov 2011 | B2 |
| 8216190 | Gartstein et al. | Jul 2012 | B2 |
| 8267889 | Cantor et al. | Sep 2012 | B2 |
| 8366677 | Kaspar et al. | Feb 2013 | B2 |
| 8696638 | Terahara et al. | Apr 2014 | B2 |
| 8702726 | Gartstein et al. | Apr 2014 | B2 |
| 8734697 | Chen et al. | May 2014 | B2 |
| 8747362 | Terahara | Jun 2014 | B2 |
| 8771781 | Tokumoto et al. | Jul 2014 | B2 |
| 8821446 | Trautman et al. | Sep 2014 | B2 |
| 8834423 | Falo, Jr. et al. | Sep 2014 | B2 |
| 8900180 | Wolter et al. | Dec 2014 | B2 |
| 8911749 | Ghartey-Tagoe et al. | Dec 2014 | B2 |
| 9114238 | Singh et al. | Aug 2015 | B2 |
| 9220678 | Kendall et al. | Dec 2015 | B2 |
| 9452280 | Singh et al. | Sep 2016 | B2 |
| 9498524 | Ghartey-Tagoe et al. | Nov 2016 | B2 |
| 9549746 | Woolfsen et al. | Jan 2017 | B2 |
| 9687640 | Trautman et al. | Jun 2017 | B2 |
| 9687641 | Singh et al. | Jun 2017 | B2 |
| 9962534 | Chen et al. | May 2018 | B2 |
| 10195409 | Bourne et al. | Feb 2019 | B2 |
| 10238848 | Singh et al. | Mar 2019 | B2 |
| 10245422 | Le et al. | Apr 2019 | B2 |
| 10384045 | Ding et al. | Aug 2019 | B2 |
| 10384046 | Bayramov et al. | Aug 2019 | B2 |
| 20010023324 | Pronovost et al. | Sep 2001 | A1 |
| 20010023351 | Eilers et al. | Sep 2001 | A1 |
| 20020006355 | Whitson | Jan 2002 | A1 |
| 20020016562 | Cormier et al. | Feb 2002 | A1 |
| 20020020688 | Sherman et al. | Feb 2002 | A1 |
| 20020032415 | Trautman et al. | Mar 2002 | A1 |
| 20020042589 | Marsoner | Apr 2002 | A1 |
| 20020045859 | Gartstein et al. | Apr 2002 | A1 |
| 20020045907 | Sherman et al. | Apr 2002 | A1 |
| 20020082543 | Park et al. | Jun 2002 | A1 |
| 20020087182 | Trautman et al. | Jul 2002 | A1 |
| 20020091357 | Trautman et al. | Jul 2002 | A1 |
| 20020096488 | Gulvin et al. | Jul 2002 | A1 |
| 20020123675 | Trautman et al. | Sep 2002 | A1 |
| 20020128599 | Cormier et al. | Sep 2002 | A1 |
| 20020133129 | Arias et al. | Sep 2002 | A1 |
| 20020133137 | Hofmann | Sep 2002 | A1 |
| 20020138049 | Allen et al. | Sep 2002 | A1 |
| 20020169411 | Sherman et al. | Nov 2002 | A1 |
| 20020177839 | Cormier et al. | Nov 2002 | A1 |
| 20020177858 | Sherman et al. | Nov 2002 | A1 |
| 20020188245 | Martin et al. | Dec 2002 | A1 |
| 20020188310 | Seward et al. | Dec 2002 | A1 |
| 20020193729 | Cormier et al. | Dec 2002 | A1 |
| 20020193819 | Porter et al. | Dec 2002 | A1 |
| 20030083645 | Angel et al. | May 2003 | A1 |
| 20030093028 | Spiegel | May 2003 | A1 |
| 20030093089 | Greenberg | May 2003 | A1 |
| 20030135167 | Gonnelli | Jul 2003 | A1 |
| 20030166624 | Gale et al. | Sep 2003 | A1 |
| 20030187394 | Wilkinson et al. | Oct 2003 | A1 |
| 20030195474 | Down et al. | Oct 2003 | A1 |
| 20030199810 | Trautman et al. | Oct 2003 | A1 |
| 20030199812 | Rosenberg | Oct 2003 | A1 |
| 20030208138 | Olson | Nov 2003 | A1 |
| 20030208167 | Prausnitz et al. | Nov 2003 | A1 |
| 20030212397 | Avrahami et al. | Nov 2003 | A1 |
| 20030220610 | Lastovich et al. | Nov 2003 | A1 |
| 20030220656 | Gartstein et al. | Nov 2003 | A1 |
| 20040049150 | Dalton et al. | Mar 2004 | A1 |
| 20040053894 | Mazess et al. | Mar 2004 | A1 |
| 20040062813 | Cormier et al. | Apr 2004 | A1 |
| 20040087893 | Kwon | May 2004 | A1 |
| 20040087992 | Gartstein et al. | May 2004 | A1 |
| 20040096455 | Maa et al. | May 2004 | A1 |
| 20040106904 | Gonnelli et al. | Jun 2004 | A1 |
| 20040143211 | Haider et al. | Jul 2004 | A1 |
| 20040146611 | Arias et al. | Jul 2004 | A1 |
| 20040164454 | Gartstein et al. | Aug 2004 | A1 |
| 20040181203 | Cormier et al. | Sep 2004 | A1 |
| 20040186419 | Cho | Sep 2004 | A1 |
| 20040204669 | Hofmann | Oct 2004 | A1 |
| 20040220535 | Canham | Nov 2004 | A1 |
| 20040236271 | Theeuwes et al. | Nov 2004 | A1 |
| 20040265365 | Daddona et al. | Dec 2004 | A1 |
| 20050049549 | Wong et al. | Mar 2005 | A1 |
| 20050065463 | Tobinaga et al. | Mar 2005 | A1 |
| 20050089554 | Cormier et al. | Apr 2005 | A1 |
| 20050090803 | Sherman et al. | Apr 2005 | A1 |
| 20050096586 | Trautman et al. | May 2005 | A1 |
| 20050163827 | Zech et al. | Jul 2005 | A1 |
| 20050178760 | Chang et al. | Aug 2005 | A1 |
| 20050197308 | Dalton | Sep 2005 | A1 |
| 20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
| 20050228340 | Cleary et al. | Oct 2005 | A1 |
| 20050256045 | Ameri et al. | Nov 2005 | A1 |
| 20050261631 | Clarke et al. | Nov 2005 | A1 |
| 20050271684 | Trautman et al. | Dec 2005 | A1 |
| 20060024358 | Santini et al. | Feb 2006 | A1 |
| 20060067943 | Maa et al. | Mar 2006 | A1 |
| 20060076718 | Sherman et al. | Apr 2006 | A1 |
| 20060095061 | Trautman et al. | May 2006 | A1 |
| 20060108914 | Young | May 2006 | A1 |
| 20060129174 | Gartstein et al. | Jun 2006 | A1 |
| 20060134188 | Podhaisky et al. | Jun 2006 | A1 |
| 20060149297 | Sherman et al. | Jul 2006 | A1 |
| 20060253079 | McDonough et al. | Nov 2006 | A1 |
| 20070027427 | Trautman et al. | Feb 2007 | A1 |
| 20070191761 | Boone et al. | Aug 2007 | A1 |
| 20070224377 | Leimbacher | Sep 2007 | A1 |
| 20070255251 | Panchula et al. | Nov 2007 | A1 |
| 20080009811 | Cantor | Jan 2008 | A1 |
| 20080009825 | Ringsred et al. | Jan 2008 | A1 |
| 20080039805 | Frederickson et al. | Feb 2008 | A1 |
| 20080063866 | Allen et al. | Mar 2008 | A1 |
| 20080114298 | Cantor et al. | May 2008 | A1 |
| 20080125743 | Yuzhakov | May 2008 | A1 |
| 20080183144 | Trautman et al. | Jul 2008 | A1 |
| 20080188771 | Boecker et al. | Aug 2008 | A1 |
| 20080195035 | Frederickson et al. | Aug 2008 | A1 |
| 20080200883 | Tomono | Aug 2008 | A1 |
| 20080208134 | Tomono | Aug 2008 | A1 |
| 20080208146 | Brandwein et al. | Aug 2008 | A1 |
| 20080214987 | Xu | Sep 2008 | A1 |
| 20080221532 | Ogawa | Sep 2008 | A1 |
| 20080262444 | Takada | Oct 2008 | A1 |
| 20080269685 | Singh et al. | Oct 2008 | A1 |
| 20090017210 | Andrianov et al. | Jan 2009 | A1 |
| 20090035446 | Kwon | Feb 2009 | A1 |
| 20090041810 | Andrianov et al. | Feb 2009 | A1 |
| 20090043279 | Kaspar et al. | Feb 2009 | A1 |
| 20090155330 | Ghartey-Tagoe et al. | Jun 2009 | A1 |
| 20090182306 | Lee et al. | Jul 2009 | A1 |
| 20090216215 | Thalmann et al. | Aug 2009 | A1 |
| 20090234301 | Tomono | Sep 2009 | A1 |
| 20100004608 | Hamamoto et al. | Jan 2010 | A1 |
| 20100028390 | Cleary et al. | Feb 2010 | A1 |
| 20100200494 | Storer | Aug 2010 | A1 |
| 20100228203 | Quan et al. | Sep 2010 | A1 |
| 20100247698 | Zhang et al. | Sep 2010 | A1 |
| 20110006458 | Sagi et al. | Jan 2011 | A1 |
| 20110028905 | Takada | Feb 2011 | A1 |
| 20110046638 | Gartstein et al. | Feb 2011 | A1 |
| 20110059150 | Kendall et al. | Mar 2011 | A1 |
| 20110098651 | Falo et al. | Apr 2011 | A1 |
| 20110121486 | Oh et al. | May 2011 | A1 |
| 20110160069 | Corrie et al. | Jun 2011 | A1 |
| 20110165236 | Chow et al. | Jul 2011 | A1 |
| 20110177139 | Jung et al. | Jul 2011 | A1 |
| 20110276027 | Trautman et al. | Nov 2011 | A1 |
| 20110276028 | Singh et al. | Nov 2011 | A1 |
| 20110280800 | Wu et al. | Nov 2011 | A1 |
| 20110288484 | Kendall et al. | Nov 2011 | A1 |
| 20110288485 | Tokumoto et al. | Nov 2011 | A1 |
| 20110295205 | Kaufmann et al. | Dec 2011 | A1 |
| 20110306853 | Black et al. | Dec 2011 | A1 |
| 20120052120 | Castor | Mar 2012 | A1 |
| 20120123297 | Brancazio | May 2012 | A1 |
| 20120123387 | Gonzalez et al. | May 2012 | A1 |
| 20120130306 | Terahara et al. | May 2012 | A1 |
| 20120150023 | Kaspar et al. | Jun 2012 | A1 |
| 20120184906 | McAllister | Jul 2012 | A1 |
| 20120330250 | Kuwahara et al. | Dec 2012 | A1 |
| 20130131598 | Trautman et al. | May 2013 | A1 |
| 20130150822 | Ross | Jun 2013 | A1 |
| 20130156849 | De Fougerolles et al. | Jun 2013 | A1 |
| 20130287832 | O'Hagan et al. | Oct 2013 | A1 |
| 20130292868 | Singh et al. | Nov 2013 | A1 |
| 20130292886 | Sagi et al. | Nov 2013 | A1 |
| 20130303502 | Cavanagh et al. | Nov 2013 | A1 |
| 20140148846 | Pereira et al. | May 2014 | A1 |
| 20140180201 | Ding et al. | Jun 2014 | A1 |
| 20140248312 | Rappuoli et al. | Sep 2014 | A1 |
| 20140257188 | Kendall et al. | Sep 2014 | A1 |
| 20140272101 | Chen et al. | Sep 2014 | A1 |
| 20140276366 | Bourne et al. | Sep 2014 | A1 |
| 20140276378 | Chen et al. | Sep 2014 | A1 |
| 20140276474 | Ding et al. | Sep 2014 | A1 |
| 20140276580 | Le et al. | Sep 2014 | A1 |
| 20140276589 | Bayramov et al. | Sep 2014 | A1 |
| 20140330198 | Zhang et al. | Nov 2014 | A1 |
| 20150079133 | Ghartey-Tagoe et al. | Mar 2015 | A1 |
| 20150238413 | Mochizuki et al. | Aug 2015 | A1 |
| 20150297878 | Singh et al. | Oct 2015 | A1 |
| 20160015952 | Omachi et al. | Jan 2016 | A1 |
| 20160058992 | Chen et al. | Mar 2016 | A1 |
| 20160067176 | Ding et al. | Mar 2016 | A1 |
| 20160135895 | Faasse et al. | May 2016 | A1 |
| 20160175572 | Crowley et al. | Jun 2016 | A1 |
| 20160374939 | Shastry et al. | Dec 2016 | A1 |
| 20170050010 | Mcallister | Feb 2017 | A1 |
| 20170217656 | Yamada | Aug 2017 | A1 |
| 20170281535 | Singh et al. | Oct 2017 | A1 |
| 20170361079 | Trautman et al. | Dec 2017 | A1 |
| 20190001109 | Kim et al. | Jan 2019 | A1 |
| 20190184147 | Singh et al. | Jun 2019 | A1 |
| 20190184148 | Le et al. | Jun 2019 | A1 |
| 20190336741 | Bayramov et al. | Nov 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2205444 | Jun 1996 | CA |
| 2376285 | Dec 2000 | CA |
| 2316534 | Mar 2001 | CA |
| 2422907 | Apr 2002 | CA |
| 2889500 | May 2014 | CA |
| 102000020 | Jun 2011 | CN |
| 102580232 | Jul 2012 | CN |
| 02319591 | Nov 1974 | DE |
| 19518974 | Nov 1995 | DE |
| 19624578 | Jan 1998 | DE |
| 0156471 | Oct 1985 | EP |
| 0240593 | Oct 1987 | EP |
| 0301599 | Feb 1989 | EP |
| 0305123 | Mar 1989 | EP |
| 0312662 | Apr 1989 | EP |
| 0400249 | Dec 1990 | EP |
| 0407063 | Jan 1991 | EP |
| 0796128 | Sep 1997 | EP |
| 1086718 | Mar 2001 | EP |
| 1086719 | Mar 2001 | EP |
| 1174078 | Jan 2002 | EP |
| 1377338 | Jun 2008 | EP |
| 2283809 | Feb 2011 | EP |
| 2399624 | Dec 2011 | EP |
| 2535602 | May 1984 | FR |
| 0788479 | Sep 1957 | GB |
| 2221394 | Feb 1990 | GB |
| 2277202 | Oct 1994 | GB |
| 46-037758 | Dec 1971 | JP |
| 60-242042 | Dec 1985 | JP |
| 62-213763 | Sep 1987 | JP |
| 01-264839 | Oct 1989 | JP |
| 02-009755 | Mar 1990 | JP |
| 03-151951 | Jun 1991 | JP |
| 05-123326 | May 1993 | JP |
| 05-162076 | Jun 1993 | JP |
| 06-238644 | Aug 1994 | JP |
| 07-132119 | May 1995 | JP |
| 08-502215 | Mar 1996 | JP |
| 09-051878 | Feb 1997 | JP |
| 54-028369 | Mar 1997 | JP |
| 09-140687 | Jun 1997 | JP |
| 09-211022 | Aug 1997 | JP |
| 10-328168 | Dec 1998 | JP |
| 11-230707 | Aug 1999 | JP |
| 11-509123 | Aug 1999 | JP |
| 2000-146777 | May 2000 | JP |
| 2000-147229 | May 2000 | JP |
| 2000-164890 | Jun 2000 | JP |
| 2000-194142 | Jul 2000 | JP |
| 2000-232095 | Aug 2000 | JP |
| 2000-232971 | Aug 2000 | JP |
| 2000-322780 | Nov 2000 | JP |
| 2000-323461 | Nov 2000 | JP |
| 2001-004442 | Jan 2001 | JP |
| 2001-138300 | May 2001 | JP |
| 2001-149485 | Jun 2001 | JP |
| 2001-157715 | Jun 2001 | JP |
| 2001-341314 | Dec 2001 | JP |
| 2002-000728 | Jan 2002 | JP |
| 2002-079499 | Mar 2002 | JP |
| 2002-151395 | May 2002 | JP |
| 2002-239014 | Aug 2002 | JP |
| 2002-301698 | Oct 2002 | JP |
| 2003-039399 | Feb 2003 | JP |
| 2003-048160 | Feb 2003 | JP |
| 2008-534881 | Nov 2003 | JP |
| 2004-065775 | Mar 2004 | JP |
| 2006271781 | Oct 2006 | JP |
| 2006-341089 | Dec 2006 | JP |
| 2007-130030 | May 2007 | JP |
| 2007-190112 | Aug 2007 | JP |
| 2007-536988 | Dec 2007 | JP |
| 2008-006178 | Jan 2008 | JP |
| 2008-074763 | Apr 2008 | JP |
| 2008-194288 | Aug 2008 | JP |
| 2009-082206 | Apr 2009 | JP |
| 2009-082207 | Apr 2009 | JP |
| 2009-201956 | Sep 2009 | JP |
| 2010-233673 | Oct 2010 | JP |
| 2010-233674 | Oct 2010 | JP |
| 20100064669 | Jun 2010 | KR |
| 2414255 | Mar 2011 | RU |
| 1641346 | Apr 1991 | SU |
| 1667864 | Aug 1991 | SU |
| WO 1993015701 | Aug 1993 | WO |
| WO 1993017754 | Sep 1993 | WO |
| WO 1994023777 | Oct 1994 | WO |
| WO 1995022612 | Aug 1995 | WO |
| WO 1995033612 | Dec 1995 | WO |
| WO 1996000109 | Jan 1996 | WO |
| WO 1996017648 | Jun 1996 | WO |
| WO 1996037155 | Nov 1996 | WO |
| WO 1996037256 | Nov 1996 | WO |
| WO 1996038174 | Dec 1996 | WO |
| WO 1997003629 | Feb 1997 | WO |
| WO 1997003718 | Feb 1997 | WO |
| WO 1997013544 | Apr 1997 | WO |
| WO 1997048440 | Dec 1997 | WO |
| WO 1997048441 | Dec 1997 | WO |
| WO 1997048442 | Dec 1997 | WO |
| WO 1998000193 | Jan 1998 | WO |
| WO 1998028307 | Jul 1998 | WO |
| WO 1999000155 | Jan 1999 | WO |
| WO 1999029298 | Jun 1999 | WO |
| WO 1999029364 | Jun 1999 | WO |
| WO 1999029365 | Jun 1999 | WO |
| WO 1999049874 | Oct 1999 | WO |
| WO 1999061888 | Dec 1999 | WO |
| WO 1999064580 | Dec 1999 | WO |
| WO 2000005166 | Feb 2000 | WO |
| WO 2003026733 | Apr 2000 | WO |
| WO 2000035530 | Jun 2000 | WO |
| WO 2000070406 | Nov 2000 | WO |
| WO 2000074763 | Dec 2000 | WO |
| WO 2000074764 | Dec 2000 | WO |
| WO 2000074765 | Dec 2000 | WO |
| WO 2000074766 | Dec 2000 | WO |
| WO 2000077571 | Dec 2000 | WO |
| WO 2001008242 | Feb 2001 | WO |
| WO 2001036037 | May 2001 | WO |
| WO 2001036321 | May 2001 | WO |
| WO 2001049362 | Jul 2001 | WO |
| WO 2002002180 | Jan 2002 | WO |
| WO 2002007543 | Jan 2002 | WO |
| WO 2002007813 | Jan 2002 | WO |
| WO 2002017985 | Mar 2002 | WO |
| WO 2002030281 | Apr 2002 | WO |
| WO 2002030301 | Apr 2002 | WO |
| WO 2002032331 | Apr 2002 | WO |
| WO 2002032480 | Apr 2002 | WO |
| WO 2002062202 | Aug 2002 | WO |
| WO 2002064193 | Aug 2002 | WO |
| WO 2002072189 | Sep 2002 | WO |
| WO 2002085446 | Oct 2002 | WO |
| WO 2002091922 | Nov 2002 | WO |
| WO 2002100474 | Dec 2002 | WO |
| WO 2003024290 | Mar 2003 | WO |
| WO 2003024518 | Mar 2003 | WO |
| WO 2004000388 | Dec 2003 | WO |
| WO 2004009172 | Jan 2004 | WO |
| WO 2004020034 | Mar 2004 | WO |
| WO 2004024224 | Mar 2004 | WO |
| WO 2004030649 | Apr 2004 | WO |
| WO 2004076339 | Sep 2004 | WO |
| WO 2004105729 | Dec 2004 | WO |
| WO 2004110717 | Dec 2004 | WO |
| WO 2005002453 | Jan 2005 | WO |
| WO 2005044333 | May 2005 | WO |
| WO 2005046769 | May 2005 | WO |
| WO 2005065765 | Jul 2005 | WO |
| WO 2005067889 | Jul 2005 | WO |
| WO 2005082596 | Sep 2005 | WO |
| WO 2005089857 | Sep 2005 | WO |
| WO 2005094526 | Oct 2005 | WO |
| WO 2005099751 | Oct 2005 | WO |
| WO 2005112984 | Dec 2005 | WO |
| WO 2006020842 | Feb 2006 | WO |
| WO 2006055795 | May 2006 | WO |
| WO 2006062848 | Jun 2006 | WO |
| WO 2006086742 | Aug 2006 | WO |
| WO 2006101459 | Sep 2006 | WO |
| WO 2007002521 | Jan 2007 | WO |
| WO 2007002522 | Jan 2007 | WO |
| WO 2007002523 | Jan 2007 | WO |
| WO 2007012114 | Feb 2007 | WO |
| WO 2007030477 | Mar 2007 | WO |
| WO 2007061964 | May 2007 | WO |
| WO 2007061972 | May 2007 | WO |
| WO 2007075806 | Jul 2007 | WO |
| WO 2007081430 | Jul 2007 | WO |
| WO 2007124411 | Nov 2007 | WO |
| WO 2008011625 | Jan 2008 | WO |
| WO 2008015236 | Feb 2008 | WO |
| WO 2008024141 | Feb 2008 | WO |
| WO 2008091602 | Jul 2008 | WO |
| WO 2008093679 | Aug 2008 | WO |
| WO 2008130587 | Oct 2008 | WO |
| WO 2008139648 | Nov 2008 | WO |
| WO 2009039013 | Mar 2009 | WO |
| WO 2009048607 | Apr 2009 | WO |
| WO 2009054988 | Apr 2009 | WO |
| WO 2009142741 | Nov 2009 | WO |
| WO 2010040271 | Apr 2010 | WO |
| WO 2010124255 | Oct 2010 | WO |
| WO 2011121023 | Oct 2011 | WO |
| WO 2011140240 | Oct 2011 | WO |
| WO 2011140274 | Oct 2011 | WO |
| WO 2012054582 | Apr 2012 | WO |
| WO 2012101639 | Aug 2012 | WO |
| WO 2012122163 | Sep 2012 | WO |
| WO 2012127249 | Sep 2012 | WO |
| WO 2012153266 | Nov 2012 | WO |
| WO 2013172999 | Nov 2013 | WO |
| WO 2014004301 | Jan 2014 | WO |
| WO 2014077244 | May 2014 | WO |
| WO 2014100750 | Jun 2014 | WO |
| WO 2014144973 | Sep 2014 | WO |
| WO 2014150069 | Sep 2014 | WO |
| WO 2014150285 | Sep 2014 | WO |
| WO 2014151654 | Sep 2014 | WO |
| WO 2014164314 | Oct 2014 | WO |
| WO 2016033540 | Mar 2016 | WO |
| WO 2016036866 | Mar 2016 | WO |
| WO 2016073908 | May 2016 | WO |
| WO 2016149152 | Sep 2016 | WO |
| WO 2017004067 | Jan 2017 | WO |
| WO 2017116076 | Jul 2017 | WO |
| Entry |
|---|
| Julinova et al., “Initiating Biodegradation of Polyvinylpyrrolidone in an Aqueous Aerobic Environment,” Proceedings of ECOpole (2012). |
| “Material Safety Data Sheet Polysorbate 80 MSDS” (2005) from ScienceLab.com. |
| International Search Report from International Patent Application No. PCT/US2016/039864 dated Sep. 23, 2016. |
| Lutrol F 68 NF, BASF Pharma Ingredients, accessed from the internet on Sep. 5, 2016 from http://www2.basf.us/Pharma/pdf/Lutrol_F_68.pdf. |
| Makaida et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier”, Polymers (Basel), vol. 3, No. 3, pp. 1377-1397 (2011). |
| International Search Report from International Patent Application No. PCT/US2011/035221 dated Jan. 10, 2012, application now published as International Publication No. WO2011/140240 on Nov. 10, 2011. |
| Avcin et al., “Subcutaneous nodule after vaccination with an aluminum-containing vaccina”, Acta Dermatoven, APA, vol. 17, No. 4, pp. 182-184 (2008). |
| Chun, et al., “An array of hollow microcapillaries for the controlled injection of genetic materials into animal/plant cells,” IEEE Workshop on Micro Electro Mechanical Systems, pp. 406-411, (1999). |
| Corbett et al., “Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model”, PLOS one,vol. 5, No. 10, pp. 1-9 (2010). |
| Database WPI / Thomson, Accession No. 2014-V89218, Gao et al., “Soluble microneedle patch useful for transdermal administration of vaccine, comprises water-soluble polymer materials as matrix material and soluble microneedle main portion”, Application No. CN10427324A, Tech Inst Phys. & Chem. Chinese Acad., 3 pages (2014). |
| “Eudragit EPO Readymix—Taste masking and moisture protection have ever been easier” Evonik Industries, Evonik Industries AG, Pharam Polymers & Services, Nov. 2014. |
| “Extended”, Meriam-Webster Online Dictionary, 6 pages, Downloaded on Sep. 7, 2010 from <http://www.merriam-webster.com/dictionary/extend>. |
| “Extended”, Macmilliam Online Dictionary, 5 pages, Downloaded on Sep. 7, 2010 from <http://www.macmillandictinoary.com/dictionary/american/extended>. |
| Ghost et al., “Influence of critical parameters of nanosuspension formulation on permeability of a poorly solube drug through the skin-A case study”, vol. 14, No. 3, pp. 1108-1117 (2013). |
| Guo et al., “Enchanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsutated antigen and adjuvant”, Int. J. Pharm., vol. 447, No. 1-2, pp. 22-30 (2013). |
| Gupta, “Aluminum compounds as vaccine adjuvants”, Adv. Drug Deliv. Rev., vol. 32, No. 3, pp. 155-172 (1998) Abstract Only. |
| Gupta and Rost, “Aluminum compounds as vaccine adjuvants”, Vaccine adjuvants: Preparation Methods and Research Protocols, O'Hagan. ed., Humana Press, Inc., Totowa, New Jersey, Meth. Mol. Med., vol. 42, No. 4, No, 4, pp. 65-89 (2000). |
| Henry, et al., “Micromachined microneedles for transdermal delivery of drugs”, IEEE Workshop on Micro Electro Mechanical Systems, New York, NY, pp. 494-498, (1998). |
| Henry, et al., “Microfabricated microneedles: A novel approach to transdermal drug delivery”, J. Pharmaceutical Science, vol. 87, No. 8, pp. 922-925, (1998). |
| “Heparin Pregnancy and Breast Feeding Warnings”, Drugs.com, Accessed Oct. 8, 2009, <http://www.drugs.com/pregnancy/heparin.html>. |
| International Search Report from International Patent Application No. PCT/US2000/015612 dated Sep. 7, 2000. |
| International Search Report from International Patent Application No. PCT/US2000/015613 dated Sep. 6, 2000. |
| International Search Report from International Patent Application No. PCT/US2000/015614 dated Sep. 6, 2000. |
| International Search Report from International Patent Application No. PCT/US2001/031977 dated Apr. 28, 2002. |
| International Search Report from International Patent Application No. PCT/US2001/031978 dated Apr. 29, 2002. |
| International Search Report from International Patent Application No. PCT/US2002/014624 dated Sep. 3, 2002. |
| International Search Report from International Patent Application No. PCT/US2002/029228 dated Apr. 23, 2003. |
| International Search Report from International Patent Application No. PCT/US2002/029245 dated Dec. 27, 2002. |
| International Search Report from International Patent Application No. PCT/US2004/005382 dated Nov. 25, 2004. |
| International Search Report from International Patent Application No. PCT/US2004/017255 dated May 24, 2005. |
| International Search Report from International Patent Application No. PCT/US2005/009854 dated Jul. 3, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/000824 dated Jul. 18, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/004943 dated Jun. 9, 2009, application now published as International Publication No. WO2008/130587 Oct. 30, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/011635 dated Dec. 19, 2008, application now published as International Publication No. WO2009/048607 on Apr. 16, 2009. |
| International Search Report from International Patent Application No. PCT/US2010/032299 dated Dec. 10, 2010, application now published as International Publication No. WO2010/124255 on Oct. 28, 2010. |
| International Search Report from International Patent Application No. PCT/US2013/077281 dated Mar. 4, 2013. |
| International Search Report from International Patent Application No. PCT/US2014/021841 dated Aug. 11, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/022087 dated May 23, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/022836 dated May 9, 2015. |
| International Search Report from International Patent Application No. PCT/US2014/022859 dated May 26, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/026179 dated Jul. 18, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/029601 dated Jul. 1, 2014. |
| International Search Report from International Patent Application No. PCT/US2015/047563 dated Nov. 20, 2015. |
| International Search Report from International Patent Application No. PCT/US2015/048161 dated Nov. 26, 2015. |
| International Search Report from International Patent Application No. PCT/US2015/059559 dated Jan. 21, 2016. |
| Keitel et al., “A randomized clinical trail of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization”, J. Infect. Dis., vol. 180, pp. 397-403 (1999). |
| Kuroda et al., “Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects”, Int. Rev. Immunol., vol. 32, No. 2, pp. 209-220 (2013). |
| Matriano, et al., “Macroflux(R) microprojection array patch technology: A new and efficient approach for intracutaneous immunization”, Pharm. Res., vol. 19, No. 1, pp. 63-70, (2002). |
| McAllister, et al., “Micromachined microneedles for transermal drug delivery”, Am. Inst. Chem. Eng., 1998 Annual Meeting, Miami Beach, FL, Nov. 15-20, Drug Delivery II, pp. 1-4. |
| Mikszta, et al., “Improved genetic immunication via micromechanical disruption of skin-barrier function and targeted epidermal delivery”, Nat. Med., vol. 8, No. 4, pp. 415-419, (2002). |
| Mikszta, et al., “Protective immunization against inhalation anthrax: A comparison of minimally invasive delivery platforms”, J. Inl. Dis., vol. 191, No. 2, pp. 278-288, (2005). |
| Munks et al., “Aluminum adjuvant elicit fibrin-dependent exracellular traps in vivo”, Blood, vol. 116, No. 24, pp. 5191-5199 (2010). |
| Papautsky, et al., “Micromachined Pipette Arrays,” MPA, Proceedings—19th international Conference—IEEE/EMBS, Chicago IL, USA, pp. 2281-2284 (1997). |
| Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery”, J. Contr. Rel., vol. 104, pp. 51-66 (2005). |
| Park, et al. “Polymer Microneedles for Controlled-Release Drug Delivery,” Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 23, No. 5, pp. 1008-1019 (2006). |
| Petrovsky and Aguilar, “Vaccine adjuvants: current state and future trends”, Immunol. Cell Biol., vol. 82, No. 5, pp. 488-496 (2004). |
| Pittman, “Aluminum-containing vaccine associated adverse events: role of route of administration and gender”, Vaccine, vol. 20, pp. s48-s50 (2002). |
| Prausnitz, et al., “Transdermal transport efficiency during skin electroporation and iontophoresis”, J. Contr. Release, vol. 38, pp. 205-217, (1996). |
| Prausnitz, “Transdermal delivery of macromolecules: Recent advances by modification of skin's barrier properties”, ACS Symposium Series No. 675, Therapeutic Protein and Peptide Formulation and Delivery, American Chemical Society, Washington DC, Chapter 8, pp. 124-153, (1997). |
| Prausnitz, “Microneedle-based vaccines”, Curr. Top. Microbiol. Immunol., vol. 333, pp. 369-393 (2009). |
| Rydberg, et al., “Low-molecular-weight heparin preventing and treating DVT”, Am. Fam. Physician, vol. 59, No. 6, pp. 1607-1612, (1999). |
| Sayers et al., “Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Applications for Analysis of Vaccine Adjuvants and Their Uses in Vaccines Development”, J. Biomed. Biotechnol., vol. 2012, Article ID: 831486, 13 pages, doi:10.1155/2012/831486 (2011). |
| Sivamani, et al., “Microneedles and transdermal applications”, Exp. Opin. Drug Del., vol. 4, No. 1, pp. 19-25, (2007). |
| Vitiello et al., “Development of a lipopetide-based therapeutic vaccine to trent chronic HBV infection”, J. Clin, Invest., vol. 95, pp. 341-349 (1995). |
| White et al., “Studies on antibody production. III. The alum granuloma”, J. Exp. Med., vol. 102, No. 1, pp. 73-82 (1955). |
| Wouters et al., “Microelectrochemical systems for drug delivery”, Electrochimica Acta., vol. 42, pp. 3385-3390, (1997). |
| Xia, et al., “Soft Lithography”, Angew. Chem. Int. Ed., vol. 37, pp. 551-575, (1998). |
| Xia, et al., “Soft Lithography”, Annu. Rev. Mater. Sci., vol. 28, pp. 153-184 (1998). |
| Kunduru et al., “Biodegradable polymers: Medical Applications”, Encyclopedia of Polymer Science and Technology, pp. 1-22 (2016) DOI: 10.1002/0471440264.pst027.pub2. |
| International Search Report from International Patent Application No. PCT/US2019/039028 dated Sep. 13, 2019. |
| Number | Date | Country | |
|---|---|---|---|
| 20160374939 A1 | Dec 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62186310 | Jun 2015 | US |
